参考文献/References:
[1] Lawrence JM,Divers J,Isom S,et al.Trends in prevalence of type 1 and type 2 diabetes in children and adolescents in the US,2001-2017[J].JAMA,2021,326(8):717-727.DOI:10.1001/jama.2021.11165.
[2] TODAY Study Group,Bjornstad P,Drews KL,et al.Long-term complications in youth-onset type 2 diabetes[J].N Engl J Med,2021,385(5):416-426.DOI:10.1056/NEJMoa2100165.
[3] Magliano DJ,Sacre JW,Harding JL,et al.Young-onset type 2 diabetes mellitus-implications for morbidity and mortality[J].Nat Rev Endocrinol,2020,16(6):321-331.DOI:10.1038/s41574-020-0334-z.
[4] Shah AS,Zeitler PS,Wong J,et al.ISPAD clinical practice consensus guidelines 2022:type 2 diabetes in children and adolescents[J].Pediatr Diabetes,2022,23(7):872-902.DOI:10.1111/pedi.13409.
[5] Zeitler P,Arslanian S,Fu J,et al.ISPAD clinical practice consensus guidelines 2018:type 2 diabetes mellitus in youth[J].Pediatr Diabetes,2018,19 Suppl 27:28-46.DOI:10.1111/pedi.12719.
[6] Wallace AS,Wang D,Shin JI,et al.Screening and diagnosis of prediabetes and diabetes in US children and adolescents[J].Pediatrics,2020,146(3):e20200265.DOI:10.1542/peds.2020-0265.
[7] US Preventive Services Task Force,Mangione CM,Barry MJ,et al.Screening for prediabetes and type 2 diabetes in children and adolescents:US preventive services task force recommendation statement[J].JAMA,2022,328(10):963-967.DOI:10.1001/jama.2022.14543.
[8] American Diabetes Association.2.Classification and diagnosis of diabetes:standards of medical care in diabetes-2021[J].Diabetes Care,2021,44(Suppl 1):S15-S33.DOI:10.2337/dc21-S002.
[9] Mayer-Davis EJ,Kahkoska AR,Jefferies C,et al.ISPAD Clinical Practice Consensus Guidelines 2018:definition,epidemiology,and classification of diabetes in children and adolescents[J].Pediatr Diabetes,2018,19 Suppl 27(Suppl 27):7-19.DOI:10.1111/pedi.12773.
[10] 中国医师协会内分泌代谢科医师分会,国家代谢性疾病临床医学研究中心.糖尿病分型诊断中国专家共识[J].中华糖尿病杂志,2022,14(2):120-139.DOI:10.3760/cma.j.cn115791-20211219-00672.
[11] 中华医学会儿科学分会内分泌遗传代谢学组.儿童青少年2型糖尿病诊治中国专家共识[J].中华儿科杂志,2017,55(6):404-410.DOI:10.3760/cma.j.issn.0578-1310.2017.06.002.
[12] ElSayed NA,Aleppo G,Aroda VR,et al.14.Children and adolescents:standards of medical care in diabetes-2023[J].Diabetes Care,2023,46(Suppl_1):S230-S253.DOI:10.2337/dc23-S014.
[13] Rubio-Cabezas O,Hattersley AT,Njølstad PR,et al.ISPAD clinical practice consensus guidelines 2014.The diagnosis and management of monogenic diabetes in children and adolescents[J].Pediatr Diabetes,2014,15 Suppl 20:47-64.DOI:10.1111/pedi.12192.
[14] Greeley SAW,Polak M,Njølstad PR,et al.ISPAD clinical practice consensus guidelines 2022:the diagnosis and management of monogenic diabetes in children and adolescents[J].Pediatr Diabetes,2022,23(8):1188-1211.DOI:10.1111/pedi.13426.
[15] Tamborlane WV,Barrientos-Pérez M,Fainberg U,et al.Liraglutide in children and adolescents with type 2 diabetes[J].N Engl J Med,2019,381(7):637-646.DOI:10.1056/NEJMoa1903822.
[16] Tamborlane WV,Bishai R,Geller D,et al.Once-weekly exenatide in youth with type 2 diabetes[J].Diabetes Care,2022,45(8):1833-1840.DOI:10.2337/dc21-2275.
[17] Arslanian SA,Hannon T,Zeitler P,et al.Once-weekly dulaglutide for the treatment of youths with type 2 diabetes[J].N Engl J Med,2022,387(5):433-443.DOI:10.1056/NEJMoa2204601.
[18] Tamborlane WV,Laffel LM,Shehadeh N,et al.Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes:a prospective,multicentre,randomised,parallel group,phase 3 study[J].Lancet Diabetes Endocrinol,2022,10(5):341-350.DOI:10.1016/S2213-8587(22)00052-3.
[19] Inge TH,Jenkins TM,Xanthakos SA,et al.Long-term outcomes of bariatric surgery in adolescents with severe obesity(FABS-5+):a prospective follow-up analysis[J].Lancet Diabetes Endocrinol,2017,5(3):165-173.DOI:10.1016/S2213-8587(16)30315-1.
[20] Inge TH,Laffel LM,Jenkins TM,et al.Comparison of surgical and medical therapy for type 2 diabetes in severely obese adolescents[J].JAMA Pediatr,2018,172(5):452-460.DOI:10.1001/jamapediatrics.2017.5763.
[21] Bjornstad P,Dart A,Donaghue KC,et al.ISPAD Clinical Practice Consensus Guidelines 2022:microvascular and macrovascular complications in children and adolescents with diabetes[J].Pediatr Diabetes,2022,23(8):1432-1450.DOI:10.1111/pedi.13444.
相似文献/References:
[1]曾静波,王姮.2型糖尿病与自身免疫反应[J].国际内分泌代谢杂志,2007,(04):259.
[2]朱素君,谢锦桃,刘军,等.二甲双胍：2型糖尿病治疗的基础药[J].国际内分泌代谢杂志,2007,(04):280.
[3]刘艳清 易秋艳 邵加庆.肠道菌群与肥胖和糖尿病的关系[J].国际内分泌代谢杂志,2015,(01):31.[doi:DOI：10.3760/cma.j.issn.1673-4157.2015.01.007]
Liu Yanqing,Yi Qiuyan,Shao Jiaqing..Relationship between gut microbiota, obesity and diabetes[J].International Journal of Endocrinology and Metabolism,2015,(01):31.[doi:DOI：10.3760/cma.j.issn.1673-4157.2015.01.007]
[4]姚旻 赵爱源 张宏.肠道菌群与2型糖尿病[J].国际内分泌代谢杂志,2015,(01):35.[doi:DOI：10.3760/cma.j.issn.1673-4157.2015.01.008]
Yao Min*,Zhao Aiyuan,Zhang Hong..Relationship between gut microbiota and type 2 diabetes[J].International Journal of Endocrinology and Metabolism,2015,(01):35.[doi:DOI：10.3760/cma.j.issn.1673-4157.2015.01.008]
[5]赵丽娟,徐宽枫,杨涛,等.SLC30A8和PTPRD基因多态性与南京地区中老年人群2型糖尿病的相关性研究[J].国际内分泌代谢杂志,2015,(03):145.[doi:10.3760/cma.j.issn.1673-4157.2015.03.001]
Zhao Lijuan*,Xu Kuanfeng,Yang Tao,et al.Relationship between SLC30A8 and PTPRD gene polymorphisms and type 2 diabetes in middle aged and elderly people in Nanjing area[J].International Journal of Endocrinology and Metabolism,2015,(01):145.[doi:10.3760/cma.j.issn.1673-4157.2015.03.001]
[6]王洁,何媛,于珮.糖尿病肾病的相关危险因素分析[J].国际内分泌代谢杂志,2015,(03):153.[doi:10.3760/cma.j.issn.1673-4157.2015.03.003]
Wang Jie*,He Yuan,Yu Pei..Risk factors of diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(01):153.[doi:10.3760/cma.j.issn.1673-4157.2015.03.003]
[7]刘帅,张萍,方毅,等.2型糖尿病合并无症状冠状动脉钙化的相关危险因素分析[J].国际内分泌代谢杂志,2015,(03):158.[doi:10.3760/cma.j.issn.1673-4157.2015.03.004]
Liu Shuai*,Zhang Ping,Fang Yi,et al.Analysis of the risk factors related with asymptomatic coronary calcification for type 2 diabetic patients[J].International Journal of Endocrinology and Metabolism,2015,(01):158.[doi:10.3760/cma.j.issn.1673-4157.2015.03.004]
[8]徐庆海,马颖,李铁马.2型糖尿病患者高甘油三酯血症-腰围表型与甲状腺功能异常的关系[J].国际内分泌代谢杂志,2015,(04):222.[doi:10.3760/cma.j.issn.1673-4157.2015.04.002]
Xu Qinghai,Ma Ying,Li Tiema..Association of hypertriglyceridaemic-waist phenotype with thyroid dysfunction in patients with type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(01):222.[doi:10.3760/cma.j.issn.1673-4157.2015.04.002]
[9]潘道延,沈洁,朱筱,等.利格列汀对2型糖尿病大鼠代谢性内毒素血症的影响[J].国际内分泌代谢杂志,2015,(04):230.[doi:10.3760/cma.j.issn.1673-4157.2015.04.004]
Pan Daoyan,Shen Jie,Zhu Xiao,et al.Effects of linagliptin on metabolic endotoxemia in type 2 diabetic rats[J].International Journal of Endocrinology and Metabolism,2015,(01):230.[doi:10.3760/cma.j.issn.1673-4157.2015.04.004]
[10]黄桥,白洁,杜洪泉.一种新的脂肪细胞因子——cartonectin[J].国际内分泌代谢杂志,2015,(04):265.[doi:10.3760/cma.j.issn.1673-4157.2015.04.014]
Huang Qiao*,Bai Jie,Du Hongquan..A novel adipokine--cartonectin[J].International Journal of Endocrinology and Metabolism,2015,(01):265.[doi:10.3760/cma.j.issn.1673-4157.2015.04.014]